Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome

@article{Kaiser2007FaecalSA,
  title={Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome},
  author={Thomas Kaiser and Jost Langhorst and Helmut Wittkowski and K Becker and Alexander W. Friedrich and Andreas Rueffer and Gustav J{\"u}rgen Dobos and Johannes Roth and Dirk Foell},
  journal={Gut},
  year={2007},
  volume={56},
  pages={1706 - 1713}
}
Objective: S100A12 is a pro-inflammatory protein that is secreted by granulocytes. S100A12 serum levels increase during inflammatory bowel disease (IBD). We performed the first study analysing faecal S100A12 in adults with signs of intestinal inflammation. Methods: Faecal S100A12 was determined by ELISA in faecal specimens of 171 consecutive patients and 24 healthy controls. Patients either suffered from infectious gastroenteritis confirmed by stool analysis (65 bacterial, 23 viral) or… Expand
Moderate performance of serum S100A12, in distinguishing inflammatory bowel disease from irritable bowel syndrome
TLDR
Increased levels of circulating S100A12 are found in IBD, compared to IBS, and may serve as an inflammatory marker in I BD, since it is well correlated with CRP and SAA. Expand
Evaluation of fecal protein S100A12 in patients with inflammatory bowel disease
TLDR
Fecal S100A12 is valuable in distinguishing inflammatory bowel disease patients versus healthy controls, however, the sensitivity and specificity are limited when compared with that described in western countries. Expand
Faecal calprotectin -- a useful tool in the management of inflammatory bowel disease.
TLDR
It appears that faecal calprotectin can detect subclinical mucosal inflammation and thus might identify patients at risk for relapse in patients with IBD and could help predict disease course. Expand
Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease.
  • J. Gisbert, A. G. McNicholl
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2009
TLDR
It has been suggested that, in inflammatory bowel disease patients receiving treatment, a normalization or decrease in faecal calprotectin concentrations is an accurate indicator of endoscopic healing. Expand
Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12
TLDR
F-S100A12 demonstrated comparable sensitivity and specificity to f-Cp and although a research tool at present, may have a future role to play in the diagnosis and management of these patients. Expand
Faecal calprotectin for screening of patients with suspected inflammatory bowel disease
TLDR
Testing for faecal calprotectin is a useful screening tool for identifying patients who are most likely to need endoscopy for suspected inflammatory bowel disease, and the discriminative power to safely excludeinflammatory bowel disease was significantly better in studies of adults than in Studies of children. Expand
Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome.
TLDR
A range of faecal markers now appears to have the potential to greatly assist in the differentiation of inflammatory bowel disease (IBD) and IBS, and some of the most promising faecic biomarkers will be discussed. Expand
Fecal calprotectin is a useful marker to diagnose ulcerative colitis from irritable bowel syndrome
TLDR
The results show that fecal calprotectin as a noninvasive method, which can be used to identify patients with ulcerative colitis from patients with irritable bowel syndrome patients has low sensitivity and specificity. Expand
Biomarkers in management of inflammatory bowel disease
TLDR
This review aims to present the actual potential of biomarker assays for faster diagnosis of IBD and their ability to monitor the disease course, predict exacerbations and improve the way IBD is managed. Expand
Fecal Calprotectin Is a Useful Marker for Disease Activity in Pediatric Patients with Inflammatory Bowel Disease
TLDR
The FC assay is a useful marker for the detection of mucosal inflammation in pediatric IBD patients and was significantly elevated in endoscopically active patients and patients with ileal wall thickening. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 73 REFERENCES
Role of faecal calprotectin as non-invasive marker of intestinal inflammation.
  • F. Costa, M. Mumolo, +6 authors G. Maltinti
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2003
TLDR
Faecal calprotectin appears to be a promising and non-invasive biomarker of intestinal inflammation and may provide a useful test for the diagnosis and follow up of inflammatory bowel diseases. Expand
Fecal S100A12: A novel noninvasive marker in children with Crohn's disease
TLDR
Fecal S100A12 was elevated in children with IBD compared with healthy control subjects, with levels closely correlated to disease activity and other serum inflammatory markers, particularly lower gut involvement. Expand
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease
TLDR
Faecal calprotectin proved to be an even stronger predictor of clinical relapse in UC than in CD, which makes the test a promising non-invasive tool for monitoring and optimising therapy. Expand
Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel disease
TLDR
Although more studies are needed to define fully the role of fecal calprotectin, convincing studies and growing clinical experience point to an expanded role in the diagnosis and management of IBD. Expand
Fecal Lactoferrin Is a Sensitive and Specific Marker in Identifying Intestinal Inflammation
TLDR
Fecal lactoferrin is sensitive and specific for detecting inflammation in chronic IBD and may prove useful in screening for inflammation in patients presenting with abdominal pain and diarrhea. Expand
Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease
TLDR
It is demonstrated that neutrophil derived S100A12 is strongly upregulated during chronic active IBD, suggesting an important role during the pathogenesis of IBD. Expand
Faecal parameters in the assessment of activity in inflammatory bowel disease.
TLDR
The value of alpha1-antitrypsin measurement in faeces in the assessment of intestinal inflammation has been well established and further studies in patients with IBD are needed to determine whether other faecal parameters, such as lactoferrin, tumour necrosis factor alpha, PMN-elastase, lysozyme, leucocyte esterase, immunoglobulin A, among others, are more accurate or cost-effective. Expand
Fecal lactoferrin as a marker for disease activity in inflammatory bowel disease: comparison with other neutrophil-derived proteins.
TLDR
Fecal Lf, PMN-E, MPO, and Lys concentrations were significantly increased in the active phase of the disease compared to the inactive phase in both UC and CD, and Lf is the most suitable of these proteins to use as neutrophil-derived fecal marker of inflammation for clinical application. Expand
Diagnostic value of faecal calprotectin in paediatric gastroenterology clinical practice.
  • R. Berni Canani, L. Rapacciuolo, +6 authors R. Troncone
  • Medicine
  • Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • 2004
TLDR
Calprotectin is a sensitive, but not disease specific, marker to easily detect inflammation throughout the whole gastrointestinal tract that may help in identifying an organic disease characterized by intestinal mucosa inflammation and in the differential diagnosis of functional bowel disorders. Expand
Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease.
TLDR
Fecal calprotectin, intestinal permeability, and positive Rome I criteria provide a safe and noninvasive means of helping differentiate between patients with organic and nonorganic intestinal disease. Expand
...
1
2
3
4
5
...